User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.

  • Open access
  • PDF
  • 390.48 K
  1. Mott Frank E., Esana Alex, Chakmakjian Carl, Herrington Jon D., Tumor Lysis Syndrome in Solid Tumors, 10.3816/sct.2005.n.012
  2. Cairo Mitchell S., Bishop Michael, Tumour lysis syndrome: new therapeutic strategies and classification, 10.1111/j.1365-2141.2004.05094.x
  3. Cairo Mitchell S., Coiffier Bertrand, Reiter Alfred, Younes Anas, , Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus : TLS Risk Classification in Adults/Children with Malignancies, 10.1111/j.1365-2141.2010.08143.x
  4. Mirrakhimov Aibek E, Tumor lysis syndrome: A clinical review, 10.5492/wjccm.v4.i2.130
  5. Vodopivec Danica Maria, Rubio Jose Enrique, Fornoni Alessia, Lenz Oliver, An Unusual Presentation of Tumor Lysis Syndrome in a Patient with Advanced Gastric Adenocarcinoma: Case Report and Literature Review, 10.1155/2012/468452
  6. Coiffier Bertrand, Altman Arnold, Pui Ching-Hon, Younes Anas, Cairo Mitchell S., Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review, 10.1200/jco.2007.15.0177
  7. Montesinos P, Martin G, Perez-Sirbent M. Identification of risk factors for tumour lysis syndrome in patients with acute myeloid leukemia: development of a prognostic score. Blood. 2005;106:1843a. abstr.
  8. Wilson F. Perry, Berns Jeffrey S., Tumor Lysis Syndrome: New Challenges and Recent Advances, 10.1053/j.ackd.2013.07.001
  9. Coiffier Bertrand, Acute Tumor Lysis Syndrome – a Rare Complication in the Treatment of Solid Tumors, 10.1159/000320581
  10. Feusner James H., Ritchey A. Kim, Cohn Susan L., Billett Amy L., Management of Tumor Lysis Syndrome: Need for Evidence-Based Guidelines, 10.1200/jco.2008.19.6030
  11. Sarno J. Prevention and management of tumor lysis syndrome in adults with malignancy. J Adv Pract Oncol. 2013;4(2):101–6.
  12. Howard Scott C., Jones Deborah P., Pui Ching-Hon, The Tumor Lysis Syndrome, 10.1056/nejmra0904569
  13. Bose P., Qubaiah O., A review of tumour lysis syndrome with targeted therapies and the role of rasburicase : TLS with targeted therapies and role of rasburicase, 10.1111/j.1365-2710.2011.01260.x
  14. Taira Fumi, Horimoto Yoshiya, Saito Mitsue, Tumor lysis syndrome following trastuzumab for breast cancer: a case report and review of the literature, 10.1007/s12282-013-0448-4
  15. Gianni Luca, Pienkowski Tadeusz, Im Young-Hyuck, Roman Laslo, Tseng Ling-Ming, Liu Mei-Ching, Lluch Ana, Staroslawska Elżbieta, de la Haba-Rodriguez Juan, Im Seock-Ah, Pedrini Jose Luiz, Poirier Brigitte, Morandi Paolo, Semiglazov Vladimir, Srimuninnimit Vichien, Bianchi Giulia, Szado Tania, Ratnayake Jayantha, Ross Graham, Valagussa Pinuccia, Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial, 10.1016/s1470-2045(11)70336-9
Bibliographic reference Baudon, Céline ; Duhoux, François ; Sinapi, Isabelle ; Canon, Jean-Luc. Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report.. In: Journal of Medical Case Reports, Vol. 10, no.1, p. 178 (2016)
Permanent URL http://hdl.handle.net/2078.1/174876